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Abstract: Despite progress in oncotherapy, cancer is still among the deadliest diseases in the Western
world, emphasizing the demand for novel treatment avenues. Cold physical plasma has shown
antitumor activity in experimental models of, e.g., glioblastoma, colorectal cancer, breast carcinoma,
osteosarcoma, bladder cancer, and melanoma in vitro and in vivo. In addition, clinical case reports
have demonstrated that physical plasma reduces the microbial contamination of severely infected
tumor wounds and ulcerations, as is often seen with head and neck cancer patients. These antimicrobial
and antitumor killing properties make physical plasma a promising tool for the treatment of head
and neck cancer. Moreover, this type of cancer is easily accessible from the outside, facilitating
the possibility of several rounds of topical gas plasma treatment of the same patient. Gas plasma
treatment of head and neck cancer induces diverse effects via the deposition of a plethora of reactive
oxygen and nitrogen species that mediate redox-biochemical processes, and ultimately, selective
cancer cell death. The main advantage of medical gas plasma treatment in oncology is the lack of
adverse events and significant side effects compared to other treatment modalities, such as surgical
approaches, chemotherapeutics, and radiotherapy, making plasma treatment an attractive strategy
for the adjuvant and palliative treatment of head and neck cancer. This review outlines the state of
the art and progress in investigating physical plasma as a novel treatment modality in the therapy of
head and neck squamous cell carcinoma.
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1. Introduction
Using the properties of physical plasma, medical gas plasma technology has been successfully
investigated for the treatment of several types of diseases. Known and upcoming applications include
decontamination, wound healing, blood coagulation, surface modifications, dentistry, and the treatment
of various medical conditions, including cancer [1–5]. The latter is among the most investigated in the
past few years because cancer mortality is still not significantly declining, current treatment schemes
often come with severe side effects, and therapy resistance is an urgent issue, even with new treatment
modalities. Therapeutic efficacy is not only vital in curative approaches but also in the palliation of
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patients where the quality of life during the remaining weeks and months of life is the therapeutic
goal [6]. Many cancer studies concerning this topic indicate that physical plasma, a partially ionized
gas that contains numerous active components, including electrons and ions, free radicals, reactive
molecules, and photons [7], might be an attractive tool in adjuvant cancer treatment [8–17]. Plasma
selectively affects cancer cells with no or little harm to the surrounding non-malignant cells in the
tissue. The selectivity of plasma toward cancer cells can be attributed to differences in their stages in the
cell cycle compared to non-malignant cells; their varying characteristics, such as the redox state; and
altered antioxidant defense mechanisms [18–20]. The detailed mechanism of action by which plasma
induces the various cancer-cell-specific effects is not well understood at the molecular level [18]. These
traits make plasma a promising technology for the minimally invasive treatment of topical tumors [19]
that are easily accessible for multiple gas plasma treatment cycles [21]. Head and neck cancer belongs
to these type of cancers, which has been investigated post plasma treatment in several studies during
the past few years. Not only in vitro and in vivo investigations have been performed, successfully
demonstrating the efficacy of physical plasma toward selectively inactivating head and neck cancer
cells (Table 1), but also several clinical investigations were conducted with so far promising results
(Table 2).
Table 1. Biological effects of physical plasma in head and neck cancer cells in vitro and in vivo.
DBD: dielectric barrier discharge; direct: immediate exposure of tissue or cells in culture vessels to
gas plasma system; indirect: exposure of a liquid to gas plasma treatment and either immediate or
delayed addition of this plasma-conditioned liquid to cells in culture or injection into the tissue. ATM:
ataxia-telangiectasia mutated, EGFR: epidermal growth factor receptor, MAPK: mitogen-activated
protein kinase, MMP: mitochondrial membrane potential, OSCC: oral squamous cell carcinoma, ROS:
reactive oxygen species, TfR: transferrin-receptor.
Main Findings and Mechanism
of Action
Treatment
Modality; Plasma
Gas and Source
Model Cell Type/AnimalModel Ref.
The ability to form colonies and cell
viability was selectively reduced in a
dose–response manner in head and neck
squamous cell carcinoma cells through
non-apoptotic mechanisms due to plasma
treatment, whereas normal oral epithelial
cells remained unaffected.
Direct; helium
plasma jet In vitro
JHU-022, JHU-028,
JHU-029, SCC25
Guerrero-Preston
et al. [19]
Physical plasma reduces cell viability,
induces DNA-damage and apoptosis in
head and neck squamous cell carcinoma.
Direct; surface
micro discharge
(SMD) in air
(MiniFlatPlaSter)
In vitro FaDu, OSC 19 Welz et al. [22]
Treatment with plasma-conditioned
liquid induces transcriptomic changes
and highly activates p53 pathway-related
genes in oral squamous cell carcinoma.
Indirect;
DC-powered
air–water plasma
jet
In vitro SCC15 Shi et al. [23]
Inactivation effect of plasma-derived
active species on oral cancer cells is higher
through a small amount of medium than
through a high amount of medium.
Direct; DBD in air In vitro HSC2 Ono et al. [24]
Plasma-derived NO radicals lead to
selective killing of oral squamous cell
carcinoma cells by targeting dysfunction
of EGFR.
Direct; nitrogen
plasma jet In vitro SCC-15, HSC-2 Lee et al. [25]
Physical plasma treatment of OSCC
induces cell death by triggering the
apoptosis pathway and increases
intracellular ROS levels.
Direct; helium
plasma jet In vitro OSCC
Ramireddy et
al. [26]
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Table 1. Cont.
Main Findings and Mechanism
of Action
Treatment
Modality; Plasma
Gas and Source
Model Cell Type/AnimalModel Ref.
The killing effects of physical plasma on
oral cancer cells depends on the amounts
of catalytic Fe(II).
Physical plasma inhibits the migration,
invasion activities, and colony-forming
abilities of oral squamous cell carcinoma
cells.
Direct; argon
Habahiro
non-equilibrium
atmospheric
pressure plasma
device
In vitro
SAS, Ca9-22,
HSC-2, HSC-3,
HSC-4, Sa3,
Ho-1-u-1
Sato et al. [27]
Plasma-treatment induced cell death of
head and neck squamous cell carcinoma
cells due to increased gene expression of
mitochondrial E3 ubiquitin-protein ligase
1 (MUL1), which inhibited the level of
AKT and p-AKT.
Plasma-conditioned liquid inhibited
tumor progression by increasing the
MUL1 level and reducing p-AKT levels in
in vivo head and neck tumor models.
Direct and indirect;
helium–oxygen
spray-type
atmospheric
pressure
non-thermal
plasma system
In vitro and
in vivo
SCC15, FaDu,
SCC-QLL1,
SCC1483, SNU1041,
SCC7, AMC-HN6
C3H/HeJ mice,
BALB/c nu/nu mice
Kim et al. [28]
Physical plasma treatment leads to the
inactivation of oral cancer cells through
the activation of apoptosis-related
proteins, such as p53, c-Jun-N-terminal
kinase (JNK), and p38.
Direct; air-oxygen
torch-type DBD In vitro HSC3 Mine et al. [29]
Physical plasma exposure generates a
large amount of oxidative stress in oral
cancer cells and has a significant
inhibitory effect on cancer cell growth
due to the promoted activation of
caspases, a compromised redox state, and
a loss of MMP that results in the decline
of cellular viability.
Direct; DBD in air In vitro KB Kaushik et al.[30]
Oral squamous cancer cell migration and
invasion is inhibited through a decreased
focal adhesion kinase expression and
matrix metalloproteinase-2/9 activity
caused by physical plasma depending on
the gas-type. Thereby, N2-plasma
inhibited cell migration and invasion the
most efficiently.
Direct;
nitrogen/helium/
argon micro-nozzle
plasma jet system
In vitro SCC1483,MSKQLL1 Kang et al. [31]
Physical plasma-induced apoptosis of
head and neck cancer cells by a
mechanism involving MAPK-mediated
mitochondrial ROS and inhibited the
growth of cancer cells in a nude mouse
xenograft model, resulting in the
accumulation of intracellular ROS.
Direct;
helium–oxygen
spray-type
atmospheric
pressure
non-thermal
plasma system
In vitro and
in vivo
FaDu, SNU1041,
SNU899, HN9
BALB/c nu/nu mice
Kang et al. [32]
Apoptosis of head and neck cancer cells is
induced by the activation of MAPK, p53
proteins, and caspase due to physical
plasma.
Direct; oxygen
torch-type DBD In vitro HSC3
Hayashi et al.
[33]
Physical plasma induces secondary
double-strand breaks (DSB) during a
short treatment time in oral cancer cells
and the number of cells with
plasma-mediated DSB decreases farther
from the irradiation center.
Direct; nitrogen
plasma jet In vitro SCC-25 Han et al. [34]
Plasma treatment specifically kills oral
squamous cell carcinoma cells via
antibody-conjugated gold nanoparticles,
and the efficiency can be enhanced
through conjugation with anti-EGFR and
anti-TfR antibodies.
Direct;
copper-polytetrafluor
oethylene-DBD in
air
In vitro SCC25 Kim et al. [35]
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Table 1. Cont.
Main Findings and Mechanism
of Action
Treatment
Modality; Plasma
Gas and Source
Model Cell Type/AnimalModel Ref.
Plasma treatment coupled with
cancer-specific antibody-conjugated gold
nanoparticles significantly decreases
cancer cell viability.
Direct;
copper-polytetrafluo
roethylene-DBD in
air
In vitro SCC25 Choi et al. [36]
Apoptosis and sub-G1 arrest were caused
by physical plasma through DNA
damage and the ATM/p53 signaling
pathway in head and neck cancer cells.
Direct;
helium–oxygen
spray-type
non-thermal
atmospheric
pressure plasma
system
In vitro
MSK QLL1,
SCC1483, SCC15,
SCC25
Chang et al.
[37]
The efficacy of plasma depends on the
treatment time, volume, and the cell type,
since head and neck cancer cells showed
more susceptibility toward plasma
treatment than the non-cancer cell line.
Indirect; argon
plasma jet In vitro SCC-15
Pereira et al.
[38]
Table 2. Impact of physical plasma treatment on squamous cell carcinoma of the head and neck region
in patients in vivo and of tumor tissue treated with plasma ex vivo.
Mechanism of Action Treatment Modality;Plasma Source Study Design/Population Ref.
Ex vivo plasma treatment of head
and neck cancer tissue biopsies
increased the number of apoptotic
cells and the levels of cytochrome c
in the extracellular liquid, indicating
apoptotic cell damage.
Cell motility significantly decreased
in head and neck squamous cell
carcinoma cells in vitro after the
physical plasma treatment.
Direct and indirect;
argon plasma jet
kINPen MED
10 patients with squamous cell carcinoma
of the head and neck: tissue samples were
collected during their preoperative
inpatient care at the clinic and subsequently
ex vivo plasma-treated.
In vitro experiments with HNO97 cells.
Hasse et al.
[6]
Application of physical plasma on
locally advanced head and neck
cancer leads to visible changes in
the tumor surface and reduces
strong odor and pain.
Direct; argon plasma
jet kINPen MED
Six patients with locally advanced (pT4)
squamous cell carcinoma of the oropharynx:
plasma treatment as part of their palliative
program and for microbial
decontamination.
Metelmann et
al. [21]
Physical plasma treatment causes
apoptosis in head and neck cancer
tissue and leads to visible effects at
the tumor surface.
Direct; argon plasma
jet kINPen MED
Group I (n = 12): Plasma treatment as part
of their palliative program and to reduce
microbiological contamination.
Group II (n = 9): curatively surgery and
received plasma treatment before total
tumor resection.
Schuster et al.
[39]
Hyperspectral imaging revealed a
relevant increase of superficial and
deeper cutaneous oxygen saturation,
hemoglobin concentration, and
distribution in plasma-treated head
and neck cancer.
Direct; argon plasma
jet kINPen MED
Patient 1 with T4 squamous cell carcinoma
of the oral cavity: plasma treatment for
microbial decontamination and as part of
the palliative concept.
Patient 2 with T3 squamous cell carcinoma
of the oral cavity: plasma treatment for
microbial decontamination and stimulation
of cell proliferation.
Rutkowski et
al. [40]
Physical plasma treatment
decreased the request for pain
medication and the typical odor due
to the reduction of microbial
contamination in patients with head
and neck cancer. Partial
plasma-treatment led to superficial
partial remission of the tumor and
wound healing.
Direct; argon plasma
jet kINPen MED
12 patients with advanced squamous cell
carcinoma of the head and neck: plasma
treatment for decontamination of the
infected cancer ulcerations as part of a
palliative program.
Metelmann et
al. [41]
Physical plasma displayed no severe
side effects, except a few mild
reactions like bad taste, exhaustion,
and bleeding in the treatment of
head and neck cancer.
Direct; argon plasma
jet kINPen MED
10 female and male patients with locally
advanced squamous cell carcinoma of the
head and neck area: for palliative
decontamination primarily focusing on the
possible side effects of plasma treatment.
Schuster et al.
[42]
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2. Head and Neck Cancer
Head and neck cancer accounts for roughly 4% of all cancers worldwide and is the sixth most
common type of cancer with over 800,000 new cases annually [43]. This type of cancer occurs more
than twice as often among men than women [44], and the average age of diagnosis is approximately
50 years old [45]. Head and neck cancer arises at several anatomical sites of the upper aerodigestive
tract, such as the oral cavity, pharynx, and larynx, whereby the most common histologic type (90%)
is the head and neck squamous cell carcinoma (HNSCC) [46]. It is widely accepted that alcohol and
tobacco over-use is associated with the majority (72%) [47,48] of this malignancy, partly through the
formation of free radicals leading to DNA damage and mutation [49,50]. Another high-risk factor is
infection with specific serotypes of human papilloma virus (HPV), especially HSP16 and HSP18. These
were established to have an etiological role in the development of HNSCC, primarily of the oropharynx.
HPV-associated HNSCC arises in younger patients more often than tobacco- and alcohol-driven
HNSCC, and are associated with prolonged survival and better treatment outcomes [51]. Despite the
ongoing discovery of new therapies and the optimization of existing therapies, head and neck cancer
remains challenging to treat due to resistance development and high genetic heterogeneity [52,53].
Conventional treatment approaches are surgical excision, chemotherapy, and radiotherapy, and
therapeutic decisions are based on the tumor location and stage. Approximately one-third of patients
display an early-stage disease, while two-thirds suffer from advanced head and neck cancer with
lymph node metastases [19]. Early-stage malignancies are predominantly treated using radiation
therapy, either alone or in combination with surgery. Chemotherapy in combination with radiation
is used as a primary treatment strategy or following surgical resection for patients with advanced
disease stages. Treatment options for recurrent disease or distant metastasis are more limited [45],
leading to poor survival outcomes and high morbidity [19]. Some of the existing chemotherapeutic
agents are poorly selective and associated with toxicities. The surgical removal of oral cancer can
result in a facial distortion with physical and psychological consequences [54], and it is sometimes not
possible because of the cancer tissue being in close vicinity to vital nerves or vasculature. In addition,
patients often develop loco-regional recurrences, distant metastases, and second primary tumors [55].
The emergence of immunotherapy, especially immune checkpoint inhibitors (ICIs), has provided
significant clinical improvements, but only about 20% of the patients respond to this kind of cancer
therapy [56]. The prognosis for patients with head and neck cancer is mainly determined by the
stage at diagnosis. It is devastating to note that survival has not markedly improved in recent
decades, with there being an average 5-year survival rate of only 40–50%, and even as poor as 25%
for hypopharyngeal cancer [55–57]. This highlights the urgent need for new treatment strategies,
experimental investigations, and discoveries of new therapeutic targets in HNSCC.
3. HNSCC and Oxidative Stress
The results of numerous investigations indicate a crucial role of physical plasma-generated
reactive oxygen and nitrogen species (ROS) for the inhibitory and antitumoral activity on cancer cells
observed with plasma treatment [58]. ROS seem to be important since they trigger the biochemistry and
redox signaling pathways necessary to promote oxidation-related changes that lead to altered cellular
functions and the activation of apoptosis [30,59]. This is because it is known that ROS are biologically
active components that modulate cellular responses in targeted cells [60]. Direct plasma treatment
primarily influences the cell physiology through the presence of highly active, short-lived ROS like
OH, O2−, NO, and HOONO, whereas indirect treatment with plasma-conditioned liquid exhibits toxic
cell effects, primarily due to long-lived species like H2O2, NO2−, and NO3− [61]. The impact of both
plasma-type-generated ROS has been described mainly for the treatment of head and neck squamous
cell carcinoma cells. Kang et al. showed the ROS-mediated inactivation of plasma-treated head and
neck cancer cells could be rescued via the addition of antioxidants, which abolished plasma-mediated
cytotoxicity through the reduction of apoptosis, levels of intracellular ROS, mitochondrial superoxide,
and the loss of mitochondrial membrane potential (MMP) [32]. Besides the initiation of cell death
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mechanisms, ROS cause the general elevation of oxidative stress within cancer cells [26]. These ROS
or secondary ROS may be able to alter cellular structures, such as DNA and RNA, and proteins
could be damaged, potentially leading to autophagy and induction of the DNA-damage response.
The latter may be a consequence of the DNA secondary double-strand breaks that have been suggested
as a consequence of plasma treatment of head and neck cancer cells [34], but this finding is likely
attributed to apoptosis induction [62]. Furthermore, cancer cells might be more prone toward ROS
than non-malignant cells since they often display a decreased antioxidant capacity, resulting in higher
susceptibility toward ROS-induced signaling responses and cell death [20].
Relating to head and neck cancer, physical plasma-generated ROS have an additional advantage.
They inhibit and decrease the microbial growth on advanced-stage tumors, which generally is an
issue because the contamination of the tissue produces a hostile odor that negatively affects social
interactions and reduces the patients’ quality of life [21]. Here, the antimicrobial efficacy of plasma [63]
aids in the palliation of the patients. Besides cold physical plasma, other therapy approaches aim
for ROS generation to target cancer selectively based on the different redox states of non-malignant
and malignant cells. Since malignant cells possess elevated intrinsic ROS generation, they are more
dependent on antioxidants for cell survival; therefore, they are more vulnerable to further oxidative
stress [20]. The chemotherapeutic agent cisplatin has been used widely in the treatment of head and
neck cancer, mostly in combination with other anticancer drugs like docetaxel, fluorouracil (5FU), or
2-deoxy-d-glucose, whereby they produce intracellular ROS and oxidative stress [64,65]. These ROS
lead to a shift in the cellular antioxidant defense capacity and the MMP, which initiates anti-proliferative
effects and apoptosis in cancer cells [30].
4. In Vitro and In Vivo Studies
Several head and neck cancer cell lines have been investigated regarding the effects of
physical plasma on their proliferation and cell activity (Table 1). Most of these experimental
in vitro studies used the oral squamous cell carcinoma cell line SCC-15, as well as SCC-25, and
highlighted their plasma-induced inactivation due to the reduction of cell growth, induction of
apoptosis, and secondary DNA damage, especially through plasma-derived ROS [19,25,28,34–38].
Other HNSCC cell lines were also tested, showing one or more of the tumor-toxic plasma-associated
characteristics [6,19,22,24,26–33,37]. In addition, HNSCC has been shown to be more prone to physical
plasma treatment than non-malignant cells since the viability of the latter did not significantly decrease
after plasma application. The fact that plasma selectively targets cancer cells, leaving non-malignant
cell types, such as human fibroblasts (e.g., human gingival fibroblast-1 (HGF-1), HS-K, and IMR-SV-90)
or human keratinocytes (HaCaT) unaffected, makes plasma a promising tool for adjuvant head and
neck cancer therapy [25,27,29]. Moreover, two studies demonstrated an enhanced selectivity of plasma
after the addition of antibody-conjugated gold nanoparticles, which specifically targeted SCC-25 head
and neck cancer cells [35,36]. Cancer cell selectivity was achieved through the conjugation of anti-EGFR
(epidermal growth factor receptor) or anti-TfR (transferrin-receptor) antibodies to the nanoparticles
since this type of cancer usually overexpresses EGFR and TfR. As a result, an 18-fold increased efficacy
of the nanoparticle treatment was found compared to the cancer cells not pretreated with plasma [35].
Therapeutic drugs often target the EGFR transmembrane protein since it plays a vital role in the
regulation of the cell cycle, proliferation, differentiation, and transformation. Hence, its degradation
leads to the inhibition of cell growth [66]. Lee et al. showed that plasma has a similar impact on
HNSCC. The plasma-derived ROS induced EGFR dysfunction and degradation in the SCC-15 and
HSC-2 cell lines, thereby interrupting the EGFR downstream signaling pathway, consequently killing
the squamous cell carcinoma [25].
Selectivity, however, is not necessarily a universal feature of gas plasma applications in cancer
treatment. Several studies have found non-malignant cells to be more vulnerable when compared to
their malignant counterparts or cancer cells in general [67–69]. This is also known from the field of
redox biology, where, for instance, human leukemia cells were less prone to ROS-induced cell death
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compared with non-malignant myeloid cells [70]. The many studies in murine animal models and the
few studies in patients (see below) nevertheless suggest that gas plasma treatment at least eradicates
tumor cells while leaving the host intact. Systemic toxicity was also not observed either in mice or
humans. Although it is unknown whether gas plasma treatment might be killing non-malignant cells
in the tumor microenvironment, the overall decline of tumor mass will, in the end, indicate whether
this technology can be usefully applied in oncology or not.
Besides EGFR, studies suggested a crucial role of the p53-signaling pathway in plasma-induced
head and neck cancer cell death [23,29,33,37]. This protein contributes to the redox balance within
the cells via regulation of the antioxidant gene expression and further senses DNA damage, initiates
signaling pathways for the DNA repair, and fulfills the role of a cell-cycle regulator [20]. Subsequently,
plasma-induced secondary DNA damage resulted in p53-mediated cell-cycle arrest in head and neck
squamous cell carcinoma cells, ultimately impairing cell viability. Thereby, p53 and its downstream
pathway are activated via phosphorylation through the ataxia-telangiectasia mutated (ATM) kinase,
inducing cellular responses, such as apoptosis, indicating the importance of the ATM/p53 pathway for
plasma-mediated head and neck cancer (HNC) cell inactivation [37]. Moreover, Hayashi et al. and
Mine et al. demonstrated the contribution of p53 during plasma-induced apoptosis. They showed
that plasma-mediated activation of mitogen-activated protein kinase (MAPK) proteins, like c-Jun
N-terminal kinase (JNK) and p38, induces p53 phosphorylation, which resulted in apoptosis of the
HNSCC cell line HSC3 [29,33].
In addition to the different signaling pathways that are induced through the physical plasma
application, the redox state of the cancer cell lines is also influenced by the plasma treatment. It has
been reported that the antioxidative activity of cancer cells is generally lower than in non-malignant
cells due to a compromised redox state, showing decreased levels of the two major redox state
regulators glutathione (GSH) and nicotinamide adenine dinucleotide phosphate (NADPH) [30,33].
The additional intracellular oxidative stress that is generated by plasma-derived ROS leads to further
imbalances in the cellular redox state and the loss of the MMP. This results in cell damage of
squamous carcinoma cells after a plasma-mediated increase of intracellular ROS levels [26,28,30,32].
Furthermore, physical-plasma-induced ROS selectively enhances the iron-dependent lipid peroxidation
and mitochondrial superoxide formation in HNSCC cells since they harbor more catalytic Fe(II) than
non-malignant cells. Consequently, the amount of catalytic Fe(II) matters for the killing efficacy of
physical plasma, suggesting the presence of ferroptosis processes during cancer cell inactivation [27].
Besides inactivation, several studies also point to a decrease in the motility of squamous cell carcinoma
cells after plasma treatment [6]. Kang et al. revealed that the migration and invasion of the head
and neck cancer cell lines MSKQLL1 and SCC1483 were significantly reduced after plasma treatment
through the downregulated expression of the focal adhesion kinase (FAK), integrin, and paxillin,
especially when utilizing N2 as a feed gas [31]. The ability to form colonies was also impaired by
plasma treatment in various HNSCC cell lines [19,27,30]. The fact that the application of different feed
gases influences the effectivity of plasma, as shown by Kang et al., demonstrates the possibility to
optimize physical plasma further for head and neck cancer treatment [31].
In contrast to the in vitro studies, only two in vivo studies have been performed regarding the
physical plasma treatment of HNSCC. The first study confirmed preliminary in vitro results by in vivo
experiments using a syngeneic mouse model, as well as a xenograft mouse model. It was demonstrated
that the application of a physical-plasma-conditioned liquid applied over one week reduced the head
and neck tumor progression through an increase of mitochondrial E3 ubiquitin-protein ligase 1 (MUL1)
expression, ultimately resulting in a decline of p-AKT levels and AKT kinase activity. Correspondingly,
the tumor weight and volume were significantly reduced in the plasma-treated group compared to
the control group [28]. Since AKT contributes to the regulation of cell survival and death in terms of
apoptosis and cancer development, it is not surprising that it plays an essential role in plasma-induced
HNC cell damage [71]. AKT degradation is mediated by MUL1, which binds to the kinase domain of
phosphorylated AKT, thereby inhibiting its downstream signaling. This finally leads to the suppression
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of cell proliferation and migration. Since the expression of MUL1 was enhanced by plasma-derived
ROS, the reactive species were also assumed to be responsible for the increased MUL1/AKT binding
observed. In untreated HNSCC cells, changes in AKT and MUL1 levels were not noticed [28].
The second study investigated the impact of plasma on the growth of FaDu HNC cells in vitro
and additionally in vivo using a nude mice xenograft model. Physical-plasma-induced apoptosis was
ascertained in the cancer cells through MAPK-mediated mitochondrial ROS and dysfunction. A rise in
the expression of p-p38, p-JNK, and p-extracellular-regulated kinase (ERK) was observed, which was
presumably intertwined in the plasma-induced cell death. The treatment not only inhibited the tumor
growth, volume, and weight after 11 days of application, but also caused increased intracellular ROS
and apoptosis within the tumor tissue in comparison to the untreated control group. Therefore, ROS
mediated the plasma-induced apoptosis in vivo and in vitro [32].
5. Clinical Studies
All clinical studies that investigated the impact of physical plasma on head and neck cancer
(Table 2) were performed with the kINPen MED (Neoplas tools GmbH, Greifswald, Germany),
which is licensed for the treatment of infected wounds, as well as infective skin diseases, and has
been described in detail before [1]. Except for one trial, the application of plasma was used for
the treatment of locally advanced squamous cell carcinoma of the head and neck region, with the
primary aim of tumor tissue decontamination as part of the palliative concept. The most apparent
plasma-induced effects were a visible change of the tumor surface similar to partial local regression,
wound healing of infected ulcerations, and the reduction of the typical fetid odor that is caused by
microbial contamination of the tumor. Regarding cancer patient palliation, a decline of requested
pain medication was observed, along with an improvement in social interaction, positive emotional
effects, and weight gain. These effects led to an overall increase in patients’ quality of life [21,39,41].
In a few patients, an 80% reduction of the tumor surface was even observed [21]. The reduction of
the tumor mass and inhibition of tumor growth was not only apparent through visible changes, but
was also confirmed on a molecular level using TUNEL (terminal deoxynucleotidyl transferase dUTP
nick end labeling) staining indicative of apoptosis within the plasma-treated tissue [21,39]. This was
confirmed in ex vivo plasma-treated tumor tissue samples, showing increased apoptosis within the
tumor tissue [6]. Molecular analysis of the liquid environment that harbored the tissues after plasma
treatment moreover revealed elevated cytochrome c levels in malignant over non-malignant samples.
This was concomitant with changes in the inflammatory signatures, as seen in elevated levels of tumor
necrosis factor-α (TNFα), interleukin-10 (IL-10), and interferon-γ (IFNγ) in plasma-treated head and
neck cancer when compared to plasma-treated non-malignant tissue.
Another trial utilized hyperspectral-imaging technology to investigate the impact of plasma on
tissue microcirculation parameters in head and neck cancer. An increase of superficial and deeper
cutaneous oxygen saturation was demonstrated that correlated with elevated hemoglobin concentration
and distribution within the plasma-treated region compared to the non-treated area. Around the spot
of plasma treatment, this effect extended locally to the adjacent region not directly being exposed to
plasma treatment. Interestingly, the effect also lasted well beyond the time when plasma treatment
was stopped. Such a plasma-mediated impact on the microcirculation may not only promote wound
healing, but may also reduce microbial contamination through an increased influx of leukocytes [40].
It is essential to mention that plasma-mediated tumor regress was only effective in some patients
(responders), while others showed no response (non-responders) [21,41]. One particular case showed a
dramatic tumor shrinkage with plasma treatment over 7 months before tumor growth relapsed, despite
the continuation of the plasma treatment further. This loss of physical plasma efficacy with long-term
treatment reveals one of the challenges in the medical application of this innovative tool since the
success seems to depend on various parameters ranging from the general genetics of the tumor to
the tumor microenvironment and possibly adaption [21]. Clonal evolution and tissue conductivity
also contribute to potential therapeutic resistance in head and neck tumors [39]. Theoretically, tissue
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conductivity may influence the production of plasma-derived ROS, thereby altering the plasma
composition itself and, as a result, its downstream effects in the tumor tissue [21].
In light of the current literature, it is difficult to assess whether gas plasma treatment of HNSCC
might be more promising in this type of tumor than other tumor types. A sophisticated comparison
with other tumor entities is currently lacking and improbable to achieve because animal models of
cancer differ in their susceptibility to treatment agents, as well as in their genetic background. However,
the clinical success of plasma treatment in HNSCC patients already demonstrates its principal capability
for having therapeutic success. It is conceivable that gas plasma treatment may not only be used
for tumor patient palliation, but also as adjuvant or neo-adjuvant therapy during radiotherapy or
chemotherapy. This way, the tumor cells might be targeted by several mechanisms simultaneously,
as we have recently demonstrated experimentally in other types of cancer cells [72–74].
Besides efficacy, safety is also a key trait of any anticancer treatment. In plasma-treated tumor
patients, no severe or serious side effects were reported during the treatment. Some patients complained
about a dry mouth, bad taste, exhaustion, and a sharp pain after longer therapy sessions [21,39,42].
Collateral edema, as well as superficial bleeding, occurred in some of the treated tumors, and in
one case, sub-mucosal necrosis was observed [41,42]. Nevertheless, unwanted effects were always
mild to moderate, but never life-threatening [42]. Even if the squamous cell carcinoma of the head
and neck region is among the easiest accessible tumors for physical plasma treatment, some tumor
areas remained badly inaccessible. This is partly because the plasma jet effluent is perpendicular
to the handpiece, while in some situations, a 60◦–90◦ tilted plasma effluent to the side would be
ideal for reaching all tumor surfaces [41]. Nevertheless, HNSCC constitutes a surgical challenge for
resection since the tumors emerge close to vital structures important for breathing, vocalization, and
swallowing, which is why physical plasma seems to be a promising tool for the treatment of this
area [6]. After dozens of plasma treatment sessions, several patients had shown desmoplastic reactions
in the tumor tissue [21,41]. This potential side effect leads to a stiff tumor topology and morphology
with abundant fibroblasts and collagen that may hamper the penetration of drugs on the one hand [75]
and ROS from consecutive plasma treatment on the other. While this is an undesired effect, gas plasma
treatment is currently employed only in HNSCC patients in the palliative setting with no therapeutic
option left, and these patients benefit substantially from plasma-mediated pain relief, antimicrobial
effects, and partial tumor regress until the disease becomes fatal.
6. Conclusions
Contrary to conventional therapeutic approaches, plasma displays nearly no side effects since it is
minimally invasive and the treatment is defined to a local region without affecting the whole organism.
Preclinical evidence points to a promising role of physical plasma in the treatment of HNSCC. However,
the clinical studies demonstrated both plasma-mediated tumor remission in some patients, while
others did not respond to the treatment at all. Therefore, further studies are needed that focus on the
question of what makes plasma treatment effective against HNSCC. This includes studying the impact
of the tumor microenvironment, the tumor microflora, the molecular determinants in HNSCC cells
that render them either sensitive or resistant to plasma treatment, and possible adaption processes
of HNSCC cells to repeated plasma application. Such findings, along with more elaborated clinical
studies, may spur the future utilization of cold physical plasma in the palliation or adjuvant treatment
of head and neck cancer patients.
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